Acuitas Investments’s Bioventus BVS Stock Holding History

Acuitas Investments’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-114,100	Closed	-$1.65M	–	36
2021 Q4	$1.65M	Buy	+114,100	New	+$1.62M	0.7%	56

Other funds holding BVS

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Acuitas Investments's BVS Position: Q1 2022 in Review

Acuitas Investments sold out of Bioventus (BVS) in Q1 2022, closing a stake of 114,100 shares — an estimated $1.65M sold.

Acuitas Investments first reported a position in BVS in Q4 2021 and held it in 1 quarter. The position peaked at $1.65M in Q4 2021. 105 funds tracked by Wall St. Rank hold BVS as of Q1 2022.

Acuitas Investments reported no remaining Bioventus position as of Q1 2022 after selling out during the quarter.
Acuitas Investments sold 114,100 Bioventus shares in Q1 2022, an estimated $1.65M.
Acuitas Investments first reported a position in Bioventus in Q4 2021 and held it in 1 quarter.
Acuitas Investments's Bioventus position peaked at $1.65M in Q4 2021.
105 funds tracked by Wall St. Rank held Bioventus as of Q1 2022.

Based on Acuitas Investments's 13F filing for Q1 2022, filed 6 May 2022.